Member Info for peterobert

BRIEF: For the six months ended 30 June 2023, Ondine Biomedical Inc revenues increased 63% to C$428K. Net loss decreased 8% to C$7.9M. Revenues reflect Canada segment increase of 49% to C$390K, United States segment increase from C$0K to C$38K. Lower net loss reflects Research and development decrease of 17% to C$2.2M (expense), General and administration decrease of 7% to C$4.7M (expense).

Fundraising

We are confident in our plans to raise capital to fund the key Phase 3 clinical trial, our ongoing commercial expansion plans, and to fund the Company's operating expenses more generally as we seek to attain short-term milestone objectives and prepare to scale further.

The rise of antimicrobial resistance ("AMR") is driving governments and research institutes to seek new solutions to combat antimicrobial-resistant pathogens and help prevent millions of deaths. Because of the demonstration of efficacy against ESKAPE and extremely drug-resistant pathogens of major concern to global health authorities, we are accelerating our pursuit of non-dilutive funding opportunities and numerous AMR-related government initiatives

RBC target of 60p looks quite achievable in 2024

as the good news continues to accumulate

and as I continue to gradually add to my holding

Expect 25p+ by year-end

is my wild estimate

dyor imho

Alberta Health Services has expanded its use of Steriwave nasal #photodisinfection to reduce the incidence of surgical site infections (SSIs) in orthopedic surgery following a successful pilot at the Mazankowski Alberta Heart Institute #infectioncontrol

This baby is going to brilliant i m h o

Expect 20p very soon

inho - dyor

Up 23% and this is only the beginning

Target 60p

Ondine to present poster at IP2023 meeting, Liverpool

Ondine Biomedical will be presenting new research at the Infection Prevention Society 2023 Conference in Liverpool, UK

Canadian life sciences company Ondine Biomedical Inc. (LON: OBI) will present results from a new in vitro study at the IP2023 Annual Conference taking place in Liverpool from 17-19 October 2023. The study evaluated the efficacy of antimicrobial photodynamic therapy (aPDT, also known as photodisinfection) against multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacteria. IP2023 is organized by the Infection Prevention Society and is the largest annual infection prevention conference in the UK and Ireland.

Antimicrobial resistance (AMR) remains a major public health concern, causing 33,000 deaths in Europe annually.[1] There are widespread multidrug-resistant (MDR) and extensively drug-resistant (XDR) infections in Europe, mainly caused by Gram-negative bacteria including Enterobacteriaceae and P. aeruginosa AMR bacteria[2],[3] and Gram-positive bacteria such as Staphylococcus spp.[4]

Photodisinfection uses a photosensitizer and a specific wavelength of light to trigger photochemical reactions that produce reactive oxygen species. These reactive oxygen species are lethal to a broad spectrum of microbes, including bacteria, fungi, and viruses. Importantly, photodisinfection does not induce antimicrobial resistance formation.

Photodisinfection is an easy-to-use alternative to topical antibiotics and antifungals because it is highly effective against all types of disease-causing pathogens, inclu8ding MDR and XDR strains.

The poster presentation, "Antimicrobial Photodynamic Therapy Against Extensively Drug-Resistant (XDR) Gram Negative Isolates With Novel Antibiotic Resistance Factors", will be presented at IP2023 between 1:10pm and 2:40pm (BST) on 18 October 2023. A further announcement providing more details of the research will be released by the Company concurrent with the start of the presentation.

Outlook

There is a huge need and growing international support for novel technologies that can address rising rates of AMR, and we are in the unique position of having a simple, cost-effective solution that does not generate resistance.

Our vision, mission, and purpose remain steadfast and clear: to bring photodisinfection to hospitals around the world to better respond to the growing antimicrobial resistance threat. With significant progress through recent and ongoing data delivery, I am excited for the months ahead and confident that we will be successful in the upcoming FDA-related and commercial milestones.

Carolyn Cross

CEO

OBI has huge potential to establish a global brand

so 60p target is not unreasonable - given time

inho - dyor

Target 60p

My personal opinion is that breakeven will happen in 2024

as more hospitals sign up to the program

The Vancouver-based life sciences company, which specialises in photodisinfection therapies reported that revenue increased 63% to CAD428,000, or GBP259,883, in the first half of 2023, from CAD262,000 the year prior.

It said this was due to additional clinical deployments of its Steriwave nasal disinfection technology in Canada, with further plans for hospital deployments later in 2023.

Ondine noted that it has commenced its first UK pilot of Steriwave with the NHS, while it is also seeking approval from the US Food & Drug Administration.

The firm posted a net loss of CAD7.9 million, narrowing from CAD8.6 million a year ago. It said the loss was due to higher clinical and regulatory costs, as well as the expansion of Ondine's commercialisation reach, it said.

Looking ahead, Ondine Chief Executive Carolyn Cross said: "There is a huge need and growing international support for novel technologies that can address rising rates of [antimicrobial resistance], and we are in the unique position of having a simple, cost-effective solution that does not generate resistance.

See - Half Year Report

100% Long

9.77-10.285

9.555-9.965

9.15-9.88

RBC projection is 60p

8.61-9.38